Literature DB >> 10496311

Digestion of C1q collagen-like domain with MMPs-1,-2,-3, and -9 further defines the sequence involved in the stimulation of neutrophil superoxide production.

S Ruiz1, A H Henschen-Edman, H Nagase, A J Tenner.   

Abstract

C1q, a subunit of the first component (C1) of the classical complement pathway, binds to neutrophils via its collagen-like region (C1q-CLR) stimulating superoxide production. We previously identified a region of C1q-CLR, defined by fragments generated by trypsin and endoLys-C digestion, that was required for triggering this respiratory burst. To further localize that critical site, purified human C1q was digested with pepsin to generate C1q-CLR, and subsequently cleaved with the matrix metalloproteinases, MMP-1, MMP-2, MMP-3, and MMP-9. Digestion of C1q-CLR with any of these MMPs did not alter the circular dichroism spectra, demonstrating that the fragments generated had maintained the secondary structure observed in the native molecule. All fragments retained the ability to trigger superoxide production by neutrophils. Analysis of the amino acid sequences of the purified cleavage products (none of which are identical to the published cleavage site specificities for these enzymes) demonstrated that it is the C-chain, but not the A-chain of C1q, that is critical for stimulating this activity, and thus may be a target for future therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10496311     DOI: 10.1002/jlb.66.3.416

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  15 in total

Review 1.  C1q receptors.

Authors:  P Eggleton; A J Tenner; K B Reid
Journal:  Clin Exp Immunol       Date:  2000-06       Impact factor: 4.330

Review 2.  How matrix metalloproteinases regulate cell behavior.

Authors:  M D Sternlicht; Z Werb
Journal:  Annu Rev Cell Dev Biol       Date:  2001       Impact factor: 13.827

Review 3.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

Review 4.  Temporal and spatial expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases following myocardial infarction.

Authors:  Merry L Lindsey; Rogelio Zamilpa
Journal:  Cardiovasc Ther       Date:  2010-07-14       Impact factor: 3.023

Review 5.  Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.

Authors:  Arda Kucukguven; Raouf A Khalil
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

Review 6.  A Comprehensive Overview of the Complex Role of Oxidative Stress in Aging, The Contributing Environmental Stressors and Emerging Antioxidant Therapeutic Interventions.

Authors:  Evripides Iakovou; Malamati Kourti
Journal:  Front Aging Neurosci       Date:  2022-06-13       Impact factor: 5.702

7.  Multiplex N-terminome analysis of MMP-2 and MMP-9 substrate degradomes by iTRAQ-TAILS quantitative proteomics.

Authors:  Anna Prudova; Ulrich auf dem Keller; Georgina S Butler; Christopher M Overall
Journal:  Mol Cell Proteomics       Date:  2010-03-20       Impact factor: 5.911

Review 8.  Matrix metalloproteinases: old dogs with new tricks.

Authors:  Robert P T Somerville; Samantha A Oblander; Suneel S Apte
Journal:  Genome Biol       Date:  2003-05-29       Impact factor: 13.583

9.  Gelatinase B/MMP-9 in Tumour Pathogenesis and Progression.

Authors:  Antonietta Rosella Farina; Andrew Reay Mackay
Journal:  Cancers (Basel)       Date:  2014-01-27       Impact factor: 6.639

10.  MMP mediated degradation of type IV collagen alpha 1 and alpha 3 chains reflects basement membrane remodeling in experimental and clinical fibrosis--validation of two novel biomarker assays.

Authors:  Jannie Marie Sand; Lise Larsen; Cory Hogaboam; Fernando Martinez; Meilan Han; Martin Røssel Larsen; Arkadiusz Nawrocki; Qinlong Zheng; Morten Asser Karsdal; Diana Julie Leeming
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.